GlassScriptPhysician profile
Sunitha Polepalle
NPI 1073613246
$4,746.06
in general payments reported to CMS, 2019-2025
17 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2021: $491 · 2022: $466 · 2023: $650 · 2024: $1,378 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,674 · Travel and Lodging: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.37 |
| Travel and Lodging | $595.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $989.99 | 2024-2025 | Tezspire, Airsupra |
| Curonix LLC | $825.01 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Janssen Pharmaceuticals, INC | $341.59 | 2019-2021 | |
| Spr Therapeutics, INC | $329.98 | 2022-2025 | Sprint Pns System |
| Sanofi-Aventis U.S. LLC | $250.00 | 2021-2025 | |
| Glaxosmithkline, LLC. | $250.00 | 2022 | |
| Novo Nordisk INC | $249.85 | 2019-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.44 | 2021-2024 | Jardiance |
| Abbott Laboratories | $231.37 | 2023-2024 | Freestyle Libre |
| Medtronic, INC. | $214.25 | 2023 | Intellis Adaptivestim |
| Amgen INC. | $212.24 | 2019-2022 | |
| Boston Scientific Corporation | $128.01 | 2019-2025 | Watchman Flx |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Uzedy |
| Jazz Pharmaceuticals INC. | $125.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.33 | 2025 | Capvaxive |
| Grt US Holding, INC. | $42.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Polepalle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.